Gemcitabine-5'-triphosphate
Sodium Salt
2',2'-Difluorocytidine-5'-triphosphate, Sodium salt
| Catálogo Nº | Apresentação | Preço (R$) | Comprar |
|---|---|---|---|
| NU-1607S | 50 μl (10 mM) | Sob demanda | Adicionar ao Carrinho |
| NU-1607L | 5 x 50 μl (10 mM) | Sob demanda | Adicionar ao Carrinho |
For general laboratory use.
Envio: shipped on gel packs
Condições de armazenamento: store at -20 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible.
Validade: 12 months after date of delivery
Fórmula molecular: C9H14N3O13P3F2 (free acid)
Peso molecular: 503.14 g/mol (free acid)
Pureza: ≥ 95 % (HPLC)
Forma: solution in water
Concentração: 10 mM - 11 mM
pH: 7.5 ±0.5
Propriedades espectroscópicas: λmax 271 nm, ε 9.1 L mmol-1 cm-1 (Tris-HCl pH 7.5)
Formulários:
Influence on epigenetic markers[1]
Treatment of hepatocellular carcinoma[2]
Treatment of bladder carcinoma[3]
Treatment of lung cancer[4]
Treatment of breast cancer[5]
Treatment of ovarien cancer[6]
Referências selecionadas:
[1] Dhayat et al. (2011) Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer- A review. International J. of Cancer 129:1031.
[2] Chua et al. (2011) Targeted therapy in hepatocellular carcinoma. International J. Hepathology 348297:11.
[3] Shelly et al. (2011) Gemcitabine chemotherapy for treatment of metastatic bladder carcinoma. BJU International 108:168.
[4] Hayashi et al. (2011) Gemcitabine:efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. Clinical Medicine Insights: Oncology 5:177.
[5] Moen et al. (2005) Gemcitabine: in combination with paclitaxel in the first line traetment of metastatic breast cancer. American J. of Cancer 4:327.
[6] Bookmann (2005) Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International J. of Gynecological Cancer 15 Suppl.1:12.